Cargando…
Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease
The 2-deoxy-d-[(18)F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) is widely utilized to assess the vascular and articular inflammatory burden of patients with a suspected diagnosis of rheumatic disease. We aimed to elucidate the impact of [(18)F]FDG PET/CT on chan...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625716/ https://www.ncbi.nlm.nih.gov/pubmed/34829421 http://dx.doi.org/10.3390/diagnostics11112073 |
_version_ | 1784606489607929856 |
---|---|
author | Fröhlich, Matthias Serfling, Sebastian Higuchi, Takahiro Pomper, Martin G. Rowe, Steven P. Schmalzing, Marc Tony, Hans-Peter Gernert, Michael Strunz, Patrick-Pascal Portegys, Jan Schwaneck, Eva-Christina Gadeholt, Ottar Weich, Alexander Buck, Andreas K. Bley, Thorsten A. Guggenberger, Konstanze V. Werner, Rudolf A. |
author_facet | Fröhlich, Matthias Serfling, Sebastian Higuchi, Takahiro Pomper, Martin G. Rowe, Steven P. Schmalzing, Marc Tony, Hans-Peter Gernert, Michael Strunz, Patrick-Pascal Portegys, Jan Schwaneck, Eva-Christina Gadeholt, Ottar Weich, Alexander Buck, Andreas K. Bley, Thorsten A. Guggenberger, Konstanze V. Werner, Rudolf A. |
author_sort | Fröhlich, Matthias |
collection | PubMed |
description | The 2-deoxy-d-[(18)F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) is widely utilized to assess the vascular and articular inflammatory burden of patients with a suspected diagnosis of rheumatic disease. We aimed to elucidate the impact of [(18)F]FDG PET/CT on change in initially suspected diagnosis in patients at the time of the scan. Thirty-four patients, who had undergone [(18)F]FDG PET/CT, were enrolled and the initially suspected diagnosis prior to [(18)F]FDG PET/CT was compared to the final diagnosis. In addition, a semi-quantitative analysis including vessel wall-to-liver (VLR) and joint-to-liver (JLR) ratios was also conducted. Prior to [(18)F]FDG PET/CT, 22/34 (64.7%) of patients did not have an established diagnosis, whereas in 7/34 (20.6%), polymyalgia rheumatica (PMR) was suspected, and in 5/34 (14.7%), giant cell arteritis (GCA) was suspected by the referring rheumatologists. After [(18)F]FDG PET/CT, the diagnosis was GCA in 19/34 (55.9%), combined GCA and PMR (GCA + PMR) in 9/34 (26.5%) and PMR in the remaining 6/34 (17.6%). As such, [(18)F]FDG PET/CT altered suspected diagnosis in 28/34 (82.4%), including in all unclear cases. VLR of patients whose final diagnosis was GCA tended to be significantly higher when compared to VLR in PMR (GCA, 1.01 ± 0.08 (95%CI, 0.95–1.1) vs. PMR, 0.92 ± 0.1 (95%CI, 0.85–0.99), p = 0.07), but not when compared to PMR + GCA (1.04 ± 0.14 (95%CI, 0.95–1.13), p = 1). JLR of individuals finally diagnosed with PMR (0.94 ± 0.16, (95%CI, 0.83–1.06)), however, was significantly increased relative to JLR in GCA (0.58 ± 0.04 (95%CI, 0.55–0.61)) and GCA + PMR (0.64 ± 0.09 (95%CI, 0.57–0.71); p < 0.0001, respectively). In individuals with a suspected diagnosis of rheumatic disease, an inflammatory-directed [(18)F]FDG PET/CT can alter diagnosis in the majority of the cases, particularly in subjects who were referred because of diagnostic uncertainty. Semi-quantitative assessment may be helpful in establishing a final diagnosis of PMR, supporting the notion that a quantitative whole-body read-out may be useful in unclear cases. |
format | Online Article Text |
id | pubmed-8625716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86257162021-11-27 Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease Fröhlich, Matthias Serfling, Sebastian Higuchi, Takahiro Pomper, Martin G. Rowe, Steven P. Schmalzing, Marc Tony, Hans-Peter Gernert, Michael Strunz, Patrick-Pascal Portegys, Jan Schwaneck, Eva-Christina Gadeholt, Ottar Weich, Alexander Buck, Andreas K. Bley, Thorsten A. Guggenberger, Konstanze V. Werner, Rudolf A. Diagnostics (Basel) Article The 2-deoxy-d-[(18)F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) is widely utilized to assess the vascular and articular inflammatory burden of patients with a suspected diagnosis of rheumatic disease. We aimed to elucidate the impact of [(18)F]FDG PET/CT on change in initially suspected diagnosis in patients at the time of the scan. Thirty-four patients, who had undergone [(18)F]FDG PET/CT, were enrolled and the initially suspected diagnosis prior to [(18)F]FDG PET/CT was compared to the final diagnosis. In addition, a semi-quantitative analysis including vessel wall-to-liver (VLR) and joint-to-liver (JLR) ratios was also conducted. Prior to [(18)F]FDG PET/CT, 22/34 (64.7%) of patients did not have an established diagnosis, whereas in 7/34 (20.6%), polymyalgia rheumatica (PMR) was suspected, and in 5/34 (14.7%), giant cell arteritis (GCA) was suspected by the referring rheumatologists. After [(18)F]FDG PET/CT, the diagnosis was GCA in 19/34 (55.9%), combined GCA and PMR (GCA + PMR) in 9/34 (26.5%) and PMR in the remaining 6/34 (17.6%). As such, [(18)F]FDG PET/CT altered suspected diagnosis in 28/34 (82.4%), including in all unclear cases. VLR of patients whose final diagnosis was GCA tended to be significantly higher when compared to VLR in PMR (GCA, 1.01 ± 0.08 (95%CI, 0.95–1.1) vs. PMR, 0.92 ± 0.1 (95%CI, 0.85–0.99), p = 0.07), but not when compared to PMR + GCA (1.04 ± 0.14 (95%CI, 0.95–1.13), p = 1). JLR of individuals finally diagnosed with PMR (0.94 ± 0.16, (95%CI, 0.83–1.06)), however, was significantly increased relative to JLR in GCA (0.58 ± 0.04 (95%CI, 0.55–0.61)) and GCA + PMR (0.64 ± 0.09 (95%CI, 0.57–0.71); p < 0.0001, respectively). In individuals with a suspected diagnosis of rheumatic disease, an inflammatory-directed [(18)F]FDG PET/CT can alter diagnosis in the majority of the cases, particularly in subjects who were referred because of diagnostic uncertainty. Semi-quantitative assessment may be helpful in establishing a final diagnosis of PMR, supporting the notion that a quantitative whole-body read-out may be useful in unclear cases. MDPI 2021-11-09 /pmc/articles/PMC8625716/ /pubmed/34829421 http://dx.doi.org/10.3390/diagnostics11112073 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fröhlich, Matthias Serfling, Sebastian Higuchi, Takahiro Pomper, Martin G. Rowe, Steven P. Schmalzing, Marc Tony, Hans-Peter Gernert, Michael Strunz, Patrick-Pascal Portegys, Jan Schwaneck, Eva-Christina Gadeholt, Ottar Weich, Alexander Buck, Andreas K. Bley, Thorsten A. Guggenberger, Konstanze V. Werner, Rudolf A. Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease |
title | Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease |
title_full | Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease |
title_fullStr | Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease |
title_full_unstemmed | Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease |
title_short | Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease |
title_sort | whole-body [(18)f]fdg pet/ct can alter diagnosis in patients with suspected rheumatic disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625716/ https://www.ncbi.nlm.nih.gov/pubmed/34829421 http://dx.doi.org/10.3390/diagnostics11112073 |
work_keys_str_mv | AT frohlichmatthias wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease AT serflingsebastian wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease AT higuchitakahiro wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease AT pompermarting wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease AT rowestevenp wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease AT schmalzingmarc wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease AT tonyhanspeter wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease AT gernertmichael wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease AT strunzpatrickpascal wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease AT portegysjan wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease AT schwaneckevachristina wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease AT gadeholtottar wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease AT weichalexander wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease AT buckandreask wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease AT bleythorstena wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease AT guggenbergerkonstanzev wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease AT wernerrudolfa wholebody18ffdgpetctcanalterdiagnosisinpatientswithsuspectedrheumaticdisease |